Literature DB >> 12010364

Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma.

S E Baldus1, S P Mönig, F-G Hanisch, T K Zirbes, U Flucke, S Oelert, G Zilkens, B Madejczik, J Thiele, P M Schneider, A H Hölscher, H P Dienes.   

Abstract

AIMS: The significance of MUC1, MUC2 and sialylated Lewis blood group antigens as prognostic markers in colorectal adenocarcinoma was investigated in a large series of patients because previous investigations revealed inconsistent results due to unrelated tumour samples from different patient groups and methodological differences. METHODS AND
RESULTS: Tissues from 243 patients with colorectal adenocarcinoma were stained immunohistochemically. MUC1 showed a strong immunoreactivity (in more than 35% of the tumour area) in 32.5%, MUC2 in 51.0%, sialyl-Lewis(x) in 67.9% and sialyl-Lewis(a) in 73.7% of the cases, respectively. MUC1 immunoreactivity displayed a significant correlation with tumour progression as reflected by advancing pTNM staging and poor differentiation. MUC2 expression was significantly stronger in mucinous adenocarcinomas. Sialyl-Lewis(x) immunostaining correlated with the extent of lymph node metastasis as well as low cytological differentiation. According to univariate and multivariate analysis (P < 0.0001) only MUC1 reactivity represented a marker of worse survival probability, opposed to the sialylated Lewis antigens that did not exert a predictive value.
CONCLUSIONS: According to our data, MUC1 and sialyl-Lewis(x) immunoreactivity exhibit statistically significant correlations with established markers of tumour progression. However, only MUC1 presents as an independent prognostic factor of colorectal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010364     DOI: 10.1046/j.1365-2559.2002.01389.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  36 in total

1.  Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease.

Authors:  Sung-Hoon Ahn; Yatrik M Shah; Junko Inoue; Keiichirou Morimura; Insook Kim; Sunhee Yim; Gilles Lambert; Reiko Kurotani; Kunio Nagashima; Frank J Gonzalez; Yusuke Inoue
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

2.  Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status.

Authors:  A Lugli; I Zlobec; K Baker; P Minoo; L Tornillo; L Terracciano; J R Jass
Journal:  J Clin Pathol       Date:  2006-06-30       Impact factor: 3.411

3.  The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection.

Authors:  David Buob; Harold Fauvel; Marie-Pierre Buisine; Stéphanie Truant; Christophe Mariette; Nicole Porchet; Agnès Wacrenier; Marie-Christine Copin; Emmanuelle Leteurtre
Journal:  Dig Dis Sci       Date:  2011-12-25       Impact factor: 3.199

Review 4.  Cancer-associated mucins: role in immune modulation and metastasis.

Authors:  Rakesh Bhatia; Shailendra K Gautam; Andrew Cannon; Christopher Thompson; Bradley R Hall; Abhijit Aithal; Kasturi Banerjee; Maneesh Jain; Joyce C Solheim; Sushil Kumar; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

Review 5.  Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Authors:  Olivera J Finn
Journal:  Exp Mol Pathol       Date:  2012-10-23       Impact factor: 3.362

6.  Mucinous colorectal adenocarcinoma: influence of mucin expression (Muc1, 2 and 5) on clinico-pathological features and prognosis.

Authors:  Rodrigo Oliva Perez; Bárbara Helou Bresciani; Cláudio Bresciani; Igor Proscurshim; Desiderio Kiss; Joaquim Gama-Rodrigues; Diego Daniel Pereira; Viviane Rawet; Ivan Cecconnello; Angelita Habr-Gama
Journal:  Int J Colorectal Dis       Date:  2008-05-06       Impact factor: 2.571

7.  Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer.

Authors:  Seung Won Kim; Ki Cheong Park; Soung Min Jeon; Tak Bum Ohn; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Cell Oncol (Dordr)       Date:  2013-02-02       Impact factor: 6.730

8.  Clinicopathological Significance of Mucin 2 Immuno-histochemical Expression in Colorectal Cancer: A Meta-Analysis.

Authors:  Li Li; Pei-Lin Huang; Xiao-Jin Yu; Xiao-Dong Bu
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

Review 9.  Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer.

Authors:  Yoshinori Inagaki; Jianjun Gao; Peipei Song; Norihiro Kokudo; Munehiro Nakata; Wei Tang
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

10.  Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.

Authors:  Emmanuel T Akporiaye; Deborah Bradley-Dunlop; Sandra J Gendler; Pinku Mukherjee; Cathy S Madsen; Tobias Hahn; David G Besselsen; Sharon M Dial; Haiyan Cui; Katrina Trevor
Journal:  Vaccine       Date:  2007-07-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.